American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131
September 28 2021 - 8:13AM
The American Brachytherapy Society (ABS) has recognized Isoray’s
Cesium-131 in its recently released new consensus statement on the
subject of low dose rate (LDR) prostate brachytherapy. This marks
the first time Cesium-131 has been included in ABS’s highly
respected consensus guidelines. Because Cesium-131 seeds were not
available as a treatment until 2004, long-term outcomes following
Cesium-131 prostate brachytherapy seeds have only recently been
available.
ABS does not rank or endorse any specific treatment option, but
rather is focused on evaluating evidence and providing insight into
research surrounding the use of brachytherapy in addressing
malignant and benign conditions.
Reacting to the newly published, evidence-based consensus
statement, Isoray CEO Lori Woods noted the importance of the
milestone. Woods said, “We are honored that this prestigious
organization has included Isoray’s Cesium-131 in these consensus
guidelines. It is another important step forward as we continue to
innovate and build on our position as a leader in prostate
brachytherapy.”
Entitled, Low dose rate brachytherapy for primary treatment of
localized prostate cancer: A systemic review and executive summary
of an evidence-based consensus statement, the findings are a
“guideline intended to present evidence-based consensus
recommendations for low dose rate (LDR) permanent seed
brachytherapy for the treatment of prostate cancer.” The paper was
the result of work by an ABS convened task force. According to the
ABS task force, the results of their comprehensive literature study
resulted in their stating that LDR prostate brachytherapy
monotherapy is an appropriate treatment option for low risk and
favorable intermediate risk disease. In combination with external
beam radiation, it also found LDR brachytherapy is appropriate for
unfavorable intermediate risk and high-risk prostate cancer
treatment.
Cesium-131 has the shortest half-life and highest energy level
of the radioisotopes that ABS currently recommends for LDR
brachytherapy for the treatment of prostate cancer. Cesium-131’s
energy is powerful, allowing it to aggressively attack the cancer
being treated. Its shorter half-life means the radiation delivers
its treatment dose faster, reducing other issues for the patient
that can come from prolonged radiation exposure. The rapid
resolution of side effects is an important advantage for patients,
allowing them to return to their normal lives quickly.
Isoray is a medical technology company and innovator in seed
brachytherapy powering expanding treatment options throughout the
body. The company is the world’s only producer of Cesium-131
brachytherapy, which treats prostate cancer and expands internal
radiation treatment for difficult to treat brain, lung,
gynecological, head and neck, pelvic, and colorectal cancers.
About
IsorayIsoray, Inc. is a
medical technology company pioneering advanced treatment
applications and devices to deliver targeted internal radiation
treatments for cancers throughout the body. Isoray, Inc., through
its subsidiary, Isoray Medical, Inc., is the sole producer of
Cesium-131 brachytherapy seeds. Learn more about this innovative
Richland, Washington company and explore the many benefits and uses
of Cesium-131 by visiting www.isoray.com. Follow us on LinkedIn and
Twitter
Contact
Media and Public Relations: Sharon Schultz (302) 539-3747
Investor Relations: Mark Levin (501) 255-1910
IsoRay (AMEX:ISR)
Historical Stock Chart
From Aug 2024 to Sep 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Sep 2023 to Sep 2024